Laura Nicoleti Zamproni

Dr. Laura Nicoleti Zamproni

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
LZLaura Nicoleti Zamproni
Laura Nicoleti Zamproni
MMMayara T. V. V. Mundim
Mayara T. V. V. Mundim
MPMarimelia Porcionatto
Marimelia Porcionatto
Graphical Bioscaffolds potential applications in tissue engineering. Bioscaffolds can be used to grow stem cells and target their differentiationin vitro(upper, left)or be used as stem cell delivery route in a brain injury(upper, right). Bioscaffolds can also contain si/miRNAs that will modify locally neural cells gene expression(lower, left)or contain exosomes/growth factors for paracrine signaling such as stimulating neurogenesis and increase neural stem migration to injury area(lower, right). This cover has been designed using resources created by Vitaly Gorbachev fromFlaticon.com.

1 March 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
LZLaura Nicoleti Zamproni
Laura Nicoleti Zamproni
MMMayara V. Mundim
Mayara V. Mundim
MPMarimelia Porcionatto
Marimelia Porcionatto
ARAnne Des Rieux
Anne Des Rieux

13 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ECElisa Marozzi Cruz
Elisa Marozzi Cruz
Lucas MachadoLucas Machado
Lucas Machado
LZLaura Nicoleti Zamproni
Laura Nicoleti Zamproni
LBLarissa Bim
Larissa Bim
PFPaula Scanavez Ferreira
Paula Scanavez Ferreira
MPMarimelia Porcionatto
Marimelia Porcionatto
Neuronal loss is the ultimate pathophysiologic event in central nervous system (CNS) diseases and replacing these neurons is one of the most significant challenges in regenerative medicine. Providing a suitable microenvironment for new neuron engraftment, proliferation, and synapse formation is a primary goal for 3D bioprinting. Among the various biomaterials, gelatin methacrylate (GelMA) stands out due to its Arg-Gly-Asp (RGD) domains, which assure its biocompatibility and degradation under physiological conditions. This work aimed to produce different GelMA-based bioink compositions, verify their mechanical and biological properties, and evaluate their ability to support neurogenesis. We evaluated four different GelMA-based bioink compositions; however, when it came to their biological properties, incorporating extracellular matrix components, such as GeltrexTM, was essential to ensure human neuroprogenitor cell viability. Finally, GeltrexTM: 8% GelMA (1:1) bioink efficiently maintained human neuroprogenitor cell stemness and supported neuronal differentiation. Interestingly, this bioink composition provides a suitable environment for murine astrocytes to de-differentiate into neural stem cells and give rise to MAP2-positive cells.

1 January 2019 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
MMMayara Vieira Mundim
Mayara Vieira Mundim
LZLaura Nicoleti Zamproni
Laura Nicoleti Zamproni
APAgnes Araújo Sardinha Pinto
Agnes Araújo Sardinha Pinto
LGLayla Testa Galindo
Layla Testa Galindo
AXAndré Machado Xavier
André Machado Xavier
MPMarimelia Porcionatto
Marimelia Porcionatto

1 January 2019 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
LZLaura Nicoleti Zamproni
Laura Nicoleti Zamproni
MGMarco A.V.M. Grinet
Marco A.V.M. Grinet
MMMayara T.V.V. Mundim
Mayara T.V.V. Mundim
MRMarcella B.C. Reis
Marcella B.C. Reis
LGLayla T. Galindo
Layla T. Galindo
MPMarimelia Porcionatto
Marimelia Porcionatto

1 April 2011 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
MLMarcos C. Lange
Marcos C. Lange
VBVera L. Braatz
Vera L. Braatz
CTCarolina Tomiyoshi
Carolina Tomiyoshi
FNFelipe M. Nóvak
Felipe M. Nóvak
AFArtur F. Fernandes
Artur F. Fernandes
LWLineu C. Werneck
Lineu C. Werneck
Neurological diseases are prevalent in the emergency room (ER). The aim of this study was to compare the neurological diagnoses between younger and older patients evaluated in the ER of a tertiary care hospital. METHOD: Patients admitted to the ER who required neurological evaluation in the first 24 hours were separated into two groups based on age, <;50 years old and >50 years old. RESULTS: Cerebrovascular disease (59.6% vs. 21.8%, p50 years old group. Seizures (8.1% vs. 18.6%, p<0.01) and primary headache (3.7% vs. 11.4%, p<0.01) were most frequent in the <;50 years old group. CONCLUSION: The current study demonstrated that these three neurological diagnoses represented the majority of the neurological evaluations in the ER. National guidelines for ER teams that treat these prevalent disorders must be included in clinical practice and training.